Stock Events

Stock Events

Anthera Pharmaceuticals 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotechnology company that develops and manufactures innovative human therapeutics, including treatments in areas that may overlap with Anthera's focus on autoimmune and inflammatory diseases.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie operates in similar therapeutic areas as Anthera, including immunology and oncology, making it a direct competitor in the biopharmaceutical market.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb is a global biopharmaceutical company with a strong portfolio in cardiovascular, oncology, and immune science, competing in the same space as Anthera.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including treatments that could be in direct competition with Anthera's products.
Pfizer
PFE
Mkt Cap152.69B
Pfizer is a global pharmaceutical corporation with a broad range of products in various therapeutic areas, including those that compete with Anthera's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of treatments for serious medical conditions, potentially competing with Anthera in the biotech space.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is known for creating transformative medicines for people with serious diseases, including cystic fibrosis, which may compete with Anthera's therapeutic areas.
Biogen
BIIB
Mkt Cap31B
Biogen is a biotechnology company that develops therapies for neurological and neurodegenerative diseases, potentially overlapping with Anthera's interest in autoimmune diseases.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including those in areas competing with Anthera.
Novartis
NVS
Mkt Cap286.78B
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide, including in areas that may compete with Anthera's product pipeline.

About

ANTHERA PHARMS INC NEW
Show more...
CEO
Paul F. Truex
Employees
21
Country
United States
ISIN
US03674U3005

Listings

STU
DE
6TA2.STU
OTC Link
US
ANTH

0 Comments

Share your thoughts

FAQ

What is Anthera Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Anthera Pharmaceuticals stocks are traded under the ticker 6TA2.STU.
How many employees does Anthera Pharmaceuticals have?▼
As of August 20, 2026, the company has 21 employees.
In which sector is Anthera Pharmaceuticals located?▼
Anthera Pharmaceuticals operates in the Health & Wellness sector.
When did Anthera Pharmaceuticals complete a stock split?▼
The last stock split for Anthera Pharmaceuticals was on May 01, 2017 with a ratio of 1:8.
Where is Anthera Pharmaceuticals headquartered?▼
Anthera Pharmaceuticals is headquartered in Houston, United States.